EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study

Nicolas Arnold iD, Julien Blanc iD, Ilaria Lucca iD, Mihai Dorin Vartolomei iD, Laila Schneidewind iD, Nicola Giudici iD, Raphael Röthlisberger iD, George N Thalmann iD, Bernhard Kiss iD, Beat Roth iD

Bladder Cancer · 2026-09 · 12 (3)

DOI: 10.1177/23523735261475431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 10.08.2026. Verfasst von Nicolas Arnold und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy.

Objective

The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach.

Methods

Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis.

Results

Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027).

Conclusions

Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.

Schlagwörter

Stichwörter der Autor:innen

BCG failurebladder cancercystectomyepirubicinhyperthermic intravesical chemotherapy (HIVEC)progressionrecurrence

Autor:innen und Institutionen

  • Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland.
  • Department of Urology, Lausanne University Hospital, Lausanne, Switzerland.
  • The Institution Organizing University Doctoral Studies (I.O.S.U.D.), Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj-Napoca, Romania.

ORCID-Profile: Nicolas Arnold, Julien Blanc, Ilaria Lucca, Mihai Dorin Vartolomei, Laila Schneidewind, Nicola Giudici, Raphael Röthlisberger, George N Thalmann, Bernhard Kiss, Beat Roth

Zitieren

APA

Arnold, N., Blanc, J., Lucca, I., Vartolomei, M. D., Schneidewind, L., Giudici, N., Röthlisberger, R., Thalmann, G. N., Kiss, B., & Roth, B. (2026). Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study. Bladder Cancer, 12(3). https://doi.org/10.1177/23523735261475431

Vancouver

Arnold N, Blanc J, Lucca I, Vartolomei MD, Schneidewind L, Giudici N, et al. Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study. Bladder Cancer. 2026;12(3). doi:10.1177/23523735261475431

BibTeX
@article{Arnold2026,
  author = {Arnold, Nicolas and Blanc, Julien and Lucca, Ilaria and Vartolomei, Mihai Dorin and Schneidewind, Laila and Giudici, Nicola and Röthlisberger, Raphael and Thalmann, George N and Kiss, Bernhard and Roth, Beat},
  title = {Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study},
  journal = {Bladder Cancer},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1177/23523735261475431}
}
Kostenlos starten →